Page last updated: 2024-12-10

2'-deoxytubercidin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2'-deoxytubercidin: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

2'-deoxytubercidin : An N-glycosylpyrrolopyrimidine that is tubercidin in which the hydroxy group at position 2 of the ribose moiety has been replaced by a hydrogen. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3006222
CHEMBL ID2074595
CHEBI ID88246
SCHEMBL ID7872094
MeSH IDM0150819

Synonyms (29)

Synonym
brn 0675913
7-(2-deoxy-beta-d-erythro-pentofuranosyl)-7h-pyrrolo(2,3-d)pyrimidin-4-amine
7-deazadeoxyadenosine
7h-pyrrolo(2,3-d)pyrimidine, 4-amino-7-(2-deoxy-beta-d-erythro-pentofuranosyl)-
7h-pyrrolo(2,3-d)pyrimidin-4-amine, 7-(2-deoxy-beta-d-erythro-pentofuranosyl)-
(2r,3s,5r)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-2-(hydroxymethyl)tetrahydrofuran-3-ol
2'-deoxytubercidin
7-deaza-2'-deoxyadenosine
deoxytubercidin
(2r,3s,5r)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-2-(hydroxymethyl)oxolan-3-ol
60129-59-1
2'-deoxy-7-deazaadenosine
bdbm50390980
CHEMBL2074595 ,
chebi:88246 ,
SCHEMBL7872094
J-700346
J-700362
NIJSNUNKSPLDTO-DJLDLDEBSA-N
(2r,3s,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-2-(hydroxymethyl)tetrahydrofuran-3-ol
7h-pyrrolo[2,3-d]pyrimidin-4-amine,7-(2-deoxy-b-d-erythro-pentofuranosyl)-
7-(2-deoxy-?-d-erythro-pentofuranosyl)-7h-pyrrolo[2,3-d]pyrimidin-4-amine
7-(2-deoxy-beta-d-ribofuranosyl)-7h-pyrrolo[2,3-d]pyrimidin-4-amine
AC-32281
CS-0100838
BCP19115
Q27160149
CS-16585
AKOS037651341
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
deoxyribonucleoside
N-glycosylpyrrolopyrimidine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 22 member 1Rattus norvegicus (Norway rat)Ki19.00000.13002.37856.9000AID679200
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 22 member 1Rattus norvegicus (Norway rat)Km23.00000.27005.695010.0000AID679195
Solute carrier family 22 member 2Rattus norvegicus (Norway rat)Km212.00009.40009.40009.4000AID681630
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (28)

Assay IDTitleYearJournalArticle
AID679200TP_TRANSPORTER: inhibition of TEA uptake in Xenopus laevis oocytes2000Biochemical pharmacology, Jul-15, Volume: 60, Issue:2
Role of organic cation transporters in the renal secretion of nucleosides.
AID217836Minimum inhibitory concentration required to reduce vaccinia virus(VV) induced cytopathogenicity by 50%1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID153257In vitro inhibitory effect was tested for cytostatic activity on the growth of lymphoid neoplasm P388 leukemic cell lines1985Journal of medicinal chemistry, Oct, Volume: 28, Issue:10
Synthesis and biological activity of certain 6-substituted and 2,6-disubstituted 2'-deoxytubercidins prepared via the stereospecific sodium salt glycosylation procedure.
AID199168Minimum inhibitory concentration required to reduce reo virus type 1 induced cytopathogenicity by 50%1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID217478Minimum inhibitory concentration required to reduce Vesicular stomatitis virus (VSV) induced cytopathogenicity by 50%1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID29734Toxic level was evaluated1985Journal of medicinal chemistry, Oct, Volume: 28, Issue:10
Synthesis and biological activity of certain 6-substituted and 2,6-disubstituted 2'-deoxytubercidins prepared via the stereospecific sodium salt glycosylation procedure.
AID96612Minimum inhibitory concentration required to reduce incorporation of [5-3H]-Urd into TCA-insoluble material from murine leukemia L1210 cells1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID204956Minimum inhibitory concentration required to reduce sindbis virus induced cytopathogenicity by 50%1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID218065Minimum cytotoxic concentration required to cause a microscopically detectable alteration of normal cell morphology in Vero cells1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID217824In vitro antiviral activity was tested against, vaccinia virus (VV)1985Journal of medicinal chemistry, Oct, Volume: 28, Issue:10
Synthesis and biological activity of certain 6-substituted and 2,6-disubstituted 2'-deoxytubercidins prepared via the stereospecific sodium salt glycosylation procedure.
AID217479Minimum inhibitory concentration required to reduce vesicular stomatitis virus (VSV) induced cytopathogenicity by 50%1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID96613Minimum inhibitory concentration required to reduce incorporation of [methyl-3H]dThd into TCA-insoluble material from murine leukemia L1210 cells1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID155586Minimum inhibitory concentration required to reduce parainfluenza type 3 induced cytopathogenicity by 50%1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID85570Minimum inhibitory concentration required to reduce Herpes simplex virus type 1 (HSV-1, strain KOS) induced cytopathogenicity by 50%1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID681630TP_TRANSPORTER: uptake (pH 5.4) in Xenopus laevis oocytes2002Biochemical pharmacology, Jul-15, Volume: 64, Issue:2
Renal organic cation and nucleoside transport.
AID54506Minimum inhibitory concentration required to reduce Coxsackie virus type B-4-induced cytopathogenicity by 50%1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID84611Minimum inhibitory concentration required to reduce Herpes simplex virus type 2 (HSV-2 strain G) induced cytopathogenicity by 50%1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID679195TP_TRANSPORTER: uptake (pH 5.4) in Xenopus laevis oocytes2002Biochemical pharmacology, Jul-15, Volume: 64, Issue:2
Renal organic cation and nucleoside transport.
AID108459In vitro antiviral activity was tested against, measles virus1985Journal of medicinal chemistry, Oct, Volume: 28, Issue:10
Synthesis and biological activity of certain 6-substituted and 2,6-disubstituted 2'-deoxytubercidins prepared via the stereospecific sodium salt glycosylation procedure.
AID96819In vitro inhibitory effect was tested for cytostatic activity on the growth of murine leukemic L1210 cell lines1985Journal of medicinal chemistry, Oct, Volume: 28, Issue:10
Synthesis and biological activity of certain 6-substituted and 2,6-disubstituted 2'-deoxytubercidins prepared via the stereospecific sodium salt glycosylation procedure.
AID96608Inhibition of murine leukemia L1210 cell growth1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID167151Minimum cytotoxic concentration required to cause a microscopically detectable alteration of normal cell morphology in primary rabbit kidney cells1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID84599In vitro antiviral activity was tested against, herpes simplex type 2 virus (HSV-2)1985Journal of medicinal chemistry, Oct, Volume: 28, Issue:10
Synthesis and biological activity of certain 6-substituted and 2,6-disubstituted 2'-deoxytubercidins prepared via the stereospecific sodium salt glycosylation procedure.
AID87798Minimum cytotoxic concentration required to cause a microscopically detectable alteration of normal cell morphology in Hela cells1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID96611Minimum inhibitory concentration required to reduce incorporation of [4,5-3H]leucine into TCA-insoluble material from murine leukemia L1210 cells1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID155439In vitro antiviral activity was tested against, parainfluenza type 3 (Para 3) virus1985Journal of medicinal chemistry, Oct, Volume: 28, Issue:10
Synthesis and biological activity of certain 6-substituted and 2,6-disubstituted 2'-deoxytubercidins prepared via the stereospecific sodium salt glycosylation procedure.
AID108456Minimum inhibitory concentration required to reduce measles virus induced cytopathogenicity by 50%1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID162251Minimum inhibitory concentration required to reduce Polio virus type 1 induced cytopathogenicity by 50%1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (31)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (19.35)18.7374
1990's5 (16.13)18.2507
2000's10 (32.26)29.6817
2010's9 (29.03)24.3611
2020's1 (3.23)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.10

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.10 (24.57)
Research Supply Index3.50 (2.92)
Research Growth Index4.59 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.10)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other32 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]